Belite Bio Makes Groundbreaking Progress in Q1 2026: Initiating NDA Rolling Submission and Preparing for Commercial Launch
Belite Bio, a leading biotechnology company focused on developing innovative treatments for retinal degenerative diseases, has made significant progress in the first quarter of 2026. During its recent earnings call, the company announced that it has received its phase III clinical study report and initiated its NDA rolling submission to the FDA for Stargardt disease.
According to Dr. Tom Lin, Chairman and CEO of Belite Bio, the company is on track to complete the submission by the second quarter of this year. This milestone marks a crucial step towards bringing Tinlarebant, the company's lead therapy candidate, to patients worldwide. As part of its commercial planning efforts, Belite Bio has hired all commercial leadership positions and continues to build out its teams in sales, market access, and medical affairs.
The company also announced that it has completed enrollment in its phase II/III DRAGON II clinical trial evaluating Tinlarebant in Stargardt disease. This registration-enabling study aims to pursue approval in Japan and has enrolled 73 adolescents and adult subjects aged 12 to 20 years from Japan, the U.S., and the U.K.
Belite Bio's financials also showed significant growth, with R&D expenses increasing to $15.7 million in Q1 2026 compared to $9.4 million in Q1 2025. The company attributed this increase to higher spending on the DRAGON II trial, increased API and drug product manufacturing expenses, and higher consultant and professional service fees.
SG&A expenses also saw a substantial jump, rising to $17 million in Q1 2026 compared to $6.1 million in Q1 2025. This increase was primarily due to share-based compensation expenses, professional service fees, and wages and salaries resulting from the company's team expansion.
Despite these increased investments, Belite Bio's balance sheet remains strong, with cash equivalents of $799 million at the end of Q1 2026. This robust financial position will enable the company to execute on its goals, including finalizing its NDA application and preparing for commercialization in Stargardt disease.
Dr. Lin emphasized that this has been a pivotal year for Belite Bio as it begins its transition to a commercial stage company. The company looks forward to providing further updates on its work in bringing therapies for retinal degenerative diseases and certain unmet medical needs.
